Bai Zhongquan, chairman of China National Pharmaceutical Group Co Ltd (Sinopharm), held talks with Pierluigi Antonelli, CEO of Fresenius Kabi, in Beijing on April 9. They reviewed more than four decades of fruitful cooperation and discussed opportunities for future development.

Hu Jianwei, Sinopharm’s deputy general manager, also attended the meeting.

Bai Zhongquan, chairman of Sinopharm, meets with a delegation led by Pierluigi Antonelli, CEO of Fresenius Kabi, in Beijing on April 9, 2025. [Photo/sinopharm.com]

Bai extended a warm welcome to the Fresenius Kabi delegation and gave a brief overview of China’s pharmaceutical industry and Sinopharm’s development. He said that since the beginning of China’s reform and opening-up, the country has achieved rapid economic growth and sustained social stability under the strong leadership of the Communist Party of China and the united efforts of the Chinese people — achievements that have also been supported by the international community, including foreign-invested enterprises operating in China.

Bai highlighted that Fresenius Kabi SSPC, a joint venture established through the collaboration between the two groups, is among the earliest Sino-foreign partnerships and has played a pivotal role in advancing China’s clinical nutrition. He also expressed Sinopharm’s commitment to strengthening its ties with Fresenius Kabi, leveraging their respective strengths to explore broader and deeper cooperation in China and neighboring markets, with the shared goal of improving public health.

Antonelli expressed his pleasure at visiting Sinopharm again. He emphasized that both groups are globally influential and highly competitive players in the pharmaceutical industry. Over the past 40 years, their partnership has been productive and rewarding, with Fresenius Kabi SSPC growing into a leading player in China’s clinical nutrition sector thanks to the strong support from both Chinese and foreign shareholders, he said.

Antonelli spoke highly of Sinopharm’s extensive commercial network in China, which has provided critical support for the localization of Fresenius Kabi SSPC’s products. Going forward, he said he hopes both sides will expand the scope of collaboration, grounded in mutual trust and complementary advantages.